Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion.
In the midst of gaining more experience in pursuing scientifically sound approaches of adaptive designs in clinical trials, a panel discussion with international representatives from industry, academia, and regulatory agencies was held at the Basel Biometric Society Spring Conference, March 12, 2010. The goal was to develop some consensus among industry, government, and academic statisticians concerning requirements and methods for adaptive designs in clinical trials. In this paper, we summarize the panelists' perspectives given at that session.
Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Norbert
N
Benda
Werner
W
Brannath
Frank
F
Bretz
Hans-Ulrich
HU
Burger
Tim
T
Friede
Willi
W
Maurer
Sue-Jane
SJ
Wang
D002986:Clinical Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data; D003627:Data Interpretation, Statistical; D017277:Drug Approval / Q000379:methods*; D017408:Guidelines as Topic; D006801:Humans; D015233:Models, Statistical; D015203:Reproducibility of Results; D012107:Research Design; D016896:Treatment Outcome; D014481:United States